Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AIM ImmunoTech Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of immunomodulatory therapies for the treatment of serious diseases with significant unmet medical need. The company operates primarily within the biotechnology and pharmaceutical research industries, with an emphasis on immune system modulation rather than direct antiviral or cytotoxic mechanisms. AIM’s activities are centered on advancing its proprietary drug candidates through clinical development and regulatory pathways rather than on commercial-stage product sales.
The company’s core asset is Ampligen® (rintatolimod), a selectively targeted Toll-like receptor 3 (TLR3) agonist designed to stimulate innate and adaptive immune responses. AIM traces its origins to Hemispherx Biopharma, Inc., which was founded in 1985 and later rebranded as AIM ImmunoTech Inc. in 2018 to reflect a refined strategic focus on immunotherapy. Over time, the company transitioned from broad antiviral research toward targeted immuno-oncology, immune-mediated disorders, and viral disease preparedness.
Business Operations
AIM ImmunoTech’s operations are organized around a single primary operating segment: immunotherapy drug development, with Ampligen® serving as the principal revenue driver through research collaborations, limited early-access programs, and grant-supported activities rather than traditional product sales. The company does not currently generate material recurring commercial revenue and remains dependent on external financing to support clinical trials and regulatory efforts.
Operational activities include clinical trial management, regulatory engagement, manufacturing oversight through third-party contractors, and scientific research partnerships. AIM conducts studies in both domestic and international settings, leveraging investigator-sponsored trials and cooperative research arrangements. The company does not report significant subsidiaries with independent operations, and its business model relies heavily on controlled intellectual property, regulatory exclusivity strategies, and external manufacturing and clinical research organizations.
Strategic Position & Investments
AIM ImmunoTech’s strategic direction is centered on expanding the clinical and potential commercial applications of Ampligen® across multiple therapeutic areas, including oncology, viral diseases, and immune-mediated disorders such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The company emphasizes platform versatility, positioning Ampligen as an immune response amplifier that may be used alone or in combination with other therapies, particularly cancer immunotherapies.
Investment activity has primarily taken the form of internal research funding, clinical trial sponsorship, and collaborations with academic institutions and government-affiliated research bodies. AIM has not reported major transformative acquisitions in recent years. Its strategic investments are focused on emerging immunological applications, combination therapy studies, and maintaining regulatory pathways in both U.S. and select international jurisdictions. Where clinical outcomes or regulatory timelines vary across studies, data inconclusive based on available public sources.
Geographic Footprint
AIM ImmunoTech is headquartered in the United States, with corporate offices located in Florida. Its primary operational and regulatory focus remains the U.S. market, particularly in engagement with the U.S. Food and Drug Administration and other federal research entities. Clinical development activities, however, extend beyond domestic borders through investigator-led and collaborative studies.
Internationally, the company has maintained a presence through clinical research and regulatory interactions in Europe and other select regions, particularly where Ampligen has historical clinical usage or investigational authorization. While AIM does not operate large-scale international facilities, its intellectual property and clinical data footprint provide it with influence across North America and parts of Europe, supporting future licensing or partnership opportunities.
Leadership & Governance
AIM ImmunoTech is led by a management team with experience in biotechnology development, regulatory strategy, and corporate governance. Leadership emphasizes a disciplined, science-driven approach focused on immune modulation as a foundational therapeutic strategy. The company’s governance structure aligns with public-company reporting requirements and oversight standards, with strategic decisions shaped by clinical evidence and capital availability.
Key executives include:
- Thomas K. Equels – Chief Executive Officer
- William A. Mitchell – Chief Financial Officer
- Dr. Dennis Klinman – Chief Scientific Officer
- Evan Jones – Chief Operating Officer
The leadership team’s stated strategic vision centers on advancing Ampligen through evidence-based clinical development, pursuing partnerships where appropriate, and positioning AIM as a specialized immunotherapy innovator rather than a broad pharmaceutical manufacturer.